SPARC (SPARC)

Turnaround

FairStock Score: 36/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Current Price₹197.98
Market Cap₹6,424.88 Cr
P/E Ratio4.06
ROCE-297.83%
ROE338.67%
Dividend Yield0%
Profit Growth59.68%
Debt/Equity0.42
Sales Growth113.93%
Promoter Holding65.67%
52-Week Range₹108 — ₹289
SectorPharmaceuticals & Biotechnology
Book Value₹41.26

Strengths

Concerns

AI Analysis

Let me apply the same test I would to any business: does it earn a return on capital, does it have a durable competitive advantage, and can I estimate its future with margin of safety? SPARC fails on every count visible here. Quarterly sales are ₹8 crore, but the net loss is ₹81 crore. That is a cash furnace, not a business. Sales have fallen 43.33% from the prior period, and book value is negative at ₹-10.63. The reported ROE of 338.67% is an illusion caused by negative equity; it is not economic earning power. ROCE of -297.83% tells me the capital employed is being destroyed. The company has no earnings, so the P/E is meaningless. I cannot value a firm by hope. The market cap of ₹4,124 crore implies a great deal of future success, but the fundamentals show a deteriorating revenue base and deepening losses. The Piotroski F-Score of 5/9 is mediocre, not a strong signal. I do take some comfort from promoter holding of 65.67%, but high ownership cannot cure a bad balance sheet. There is no dividend yield, so investors must rely entirely on capital appreciation, which itself depends on a turnaround I cannot confirm. The stock is closer to its 52-week low of ₹108 than its high of ₹289, but a falling price is not an invitation when the underlying value is negative. Without profits, positive book value, or any sign of an economic moat, this is not an investment in a business; it is speculation on an uncertain outcome. In Graham's language, the margin of safety is absent. FairStock Score of 0/100 says the same. I will pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer